Aligos Therapeutics (ALGS) EBIT Margin (2021 - 2026)
Aligos Therapeutics (ALGS) reported EBIT Margin of 951.55% for Q1 2026, up 523591.0% on a YoY basis from N/an in Q1 2025, and down 102.63% quarter-over-quarter from 36186.98% in Q4 2025.
Aligos Therapeutics (ALGS) EBIT Margin (2021 - 2026) Analysis & Trends
Aligos Therapeutics has reported EBIT Margin for 6 years, with the latest figure at 951.55% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin rose 523591.0% year-over-year to 951.55%; the trailing twelve-month figure through Mar 2026 stood at 269.95% (up 240512.0% YoY), and the FY2025 full-year result was 229.41%, up 223954.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 951.55%, down from 36186.98% in the prior quarter.
- The five-year high for EBIT Margin was 36186.98% in Q4 2025, with the low at 6187.46% in Q1 2025.
- Historically, EBIT Margin has averaged 510.97% across 5 years, with a median of 1383.0% in 2022.
- The largest YoY upside for EBIT Margin was 3958022 bps in 2025 against a maximum downside of 301080 bps in 2025.
- Aligos Therapeutics' EBIT Margin stood at 641.28% in 2022, then retreated by 6 bps to 680.73% in 2023, then plunged by 398 bps to 3393.23% in 2024, then surged by 1166 bps to 36186.98% in 2025, then plunged by 103 bps to 951.55% in 2026.
- The last three EBIT Margin figures came in at 951.55% (Q1 2026), 36186.98% (Q4 2025), and 3827.4% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Aligos Therapeutics | 51.70 Mn | -28.13 Mn | - | -951.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -951.55% |
| Dec 31, 2025 | 36,186.98% |
| Sep 30, 2025 | -3,827.40% |
| Jun 30, 2025 | -1,924.04% |
| Mar 31, 2025 | -6,187.46% |
| Dec 31, 2024 | -3,393.23% |
| Sep 30, 2024 | -1,610.48% |
| Jun 30, 2024 | -2,489.54% |
| Mar 31, 2024 | -3,176.66% |
| Dec 31, 2023 | -680.73% |
| Sep 30, 2023 | -885.38% |
| Jun 30, 2023 | -445.76% |
| Mar 31, 2023 | -925.98% |
| Dec 31, 2022 | -641.28% |
| Mar 31, 2022 | -1,383.00% |
| Dec 31, 2021 | -10,340.05% |
| Sep 30, 2021 | -2,151.46% |
| Jun 30, 2021 | -1,913.59% |
| Mar 31, 2021 | -3,048.35% |